Birmingham, ALNCT07224529Now EnrollingIRB Ready

Meibomian Gland Dysfunction (MGD) Clinical Trial in Birmingham, AL

Access cutting-edge meibomian gland dysfunction (mgd) treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by University of Alabama at Birmingham

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access meibomian gland dysfunction (mgd) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related meibomian gland dysfunction (mgd) treatment provided free

Apply for This Birmingham Location

Check if you qualify for this meibomian gland dysfunction (mgd) clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This Meibomian Gland Dysfunction (MGD) Study in Birmingham

This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes. If you join the study, after a short "run-in" period using artificial tears, you will receive Vevye twice a day for about 24 weeks (approximately six months). During that time you will attend several clinic visits where your eye symptoms, lid health, tear film, and meibomian gland function will be assessed. The goal is to learn whether Vevye improves symptoms (like eye dryness or irritation) and signs (such as changes on the eye's surface or lid margins) of MGD. You will also be monitored for safety and comfort of the eye drop. The information obtained from this study may help determine whether this treatment is beneficial for people with this condition and contribute to future care options. Participation is voluntary and you may stop at any time.

Sponsor: University of Alabama at Birmingham

Who Can Participate

Inclusion Criteria

Age \> 18 years
VAS Dryness \> 70
Posterior lid margin hyperemia grade 2 or worse for both eyes
Corneal fluorescein staining \> 6 (NEI scale) for at least one eye
Modified meibomian gland expression score ≥ 23 for both eyes OR ≥ 7 for expressible glands for both eyes OR a combination of the two
Unanesthetized Schirmer ≥ 5 mm in 5 minutes for both eyes

Exclusion Criteria

Age \> 18 years
VAS Dryness \> 70
Posterior lid margin hyperemia grade 2 or worse for both eyes
Corneal fluorescein staining \> 6 (NEI scale) for at least one eye
Modified meibomian gland expression score ≥ 23 for both eyes OR ≥ 7 for expressible glands for both eyes OR a combination of the two
Unanesthetized Schirmer ≥ 5 mm in 5 minutes for both eyes 4.2 EXCLUSION CRITERIA
Contact lens wear within two weeks of study enrollment or planned during study period
Habitual visual acuity worse than 0.30 logMAR in either eye
Previous or current diagnosis of any of the following conditions:
Sjögren's disease
Stevens-Johnson syndrome
Keratoconus
Herpetic keratitis
Any other condition that in the opinion of the clinician would interfere with study parameters
Use of any of the following medications within 30 days of enrollment:
Topical ophthalmic cyclosporine (including but not limited to Restasis®, Cequa®, Vevye®, generic, or compounded versions)
Topical ocular steroids
Any topical anti-glaucoma medication
Any of the following procedural treatments for MGD within 6 months of enrollment:
Intense pulsed light (IPL)
Therapeutic gland expression
Any other procedure targeting the meibomian glands
Insertion or removal of permanent punctal plugs within 3 months of enrollment
Insertion of dissolvable punctal plugs within 9 months of enrollment (or within 3 months of expected dissolution date, if known)
Presence of active ocular allergies
Previous intraocular surgery within 6 months of enrollment
Previous refractive surgery within 2 years of enrollment
Current or planned pregnancy during the study period
Current or planned lactation during the study period
Females of childbearing potential who are not using effective contraception
Known allergy or sensitivity to the study drug
Dose modification of oral antihistamines or antidepressants within 1 month of enrollment
Current enrollment or enrollment within 60 days in any other study of an investigational drug or device
Clinical opinion of the study doctor based on clinical examination and/or participant compliance with protocol requirements

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT07224529) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Meibomian Gland Dysfunction (MGD) Treatment Options in Birmingham, AL

If you're searching for meibomian gland dysfunction (mgd) treatment options in Birmingham, AL, this clinical trial (NCT07224529) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced meibomian gland dysfunction (mgd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all meibomian gland dysfunction (mgd) clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Birmingham, AL

See all heart attack clinical trials recruiting in Birmingham — not just this study.

Browse Heart Attack Trials in Birmingham →

Browse More Trials by Condition

Heart Attack TrialsMyasthenia Gravis TrialsMyocardial Infarction TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL